Entrada Therapeutics Inc

For the period ended Dec 31, 2023. Filed Mar 13, 2024.

About this filing

A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.

FY2023 · Filed Mar 13, 2024

TRDA$4.69-4.1%Stored close · as of Nov 9, 2026

Extracted filing text, with the paragraph anchors used by the comparison.

See the whole filing, with its images and exhibits

Contents

Consolidated Statements of tockholders’ Equity

CONSOLIDATED STATEMENTS OF STOCKHOLDERS’ EQUITY

(In thousands, except share amounts)

Common Stock · Additional Paid‑in Capital · Accumulated Other Comprehensive Income (Loss) · Accumulated Deficit · Total Stockholders’ Equity
Shares · Amount
Balances at December 31, 2021	31,224,336	$3		$392,384		$—			$(93,669)	$298,718
Issuance of common stock upon exercise of stock options	84,526	—	195		—	—		195
Vesting of early exercised options	58,015	—	135		—	—		135
Purchase of common stock under the employee stock purchase plan	27,890	—	284		—	—		284
Stock‑based compensation	—	—	9,895		—	—		9,895
Other comprehensive loss	—	—	—		(2,057)	—		(2,057)
Net loss	—	—	—		—	(94,616)		(94,616)
Balances at December 31, 2022	31,394,767	$3		$402,893		$(2,057)			$(188,285)	$212,554
Issuance of common stock upon exercise of stock options	214,078	—	1,187		—	—		1,187
Issuance of common stock in connection with the Vertex Agreement	1,618,613	—	19,407		—	—		19,407
Vesting of early exercised options	33,416	—	91		—	—		91
Vesting of restricted stock units	138,361	—	—		—	—		—
Purchase of common stock under the employee stock purchase plan	38,061	—	443		—	—		443
Stock‑based compensation	—	—	13,111		—	—		13,111
Other comprehensive income	—	—	—		2,252		—		2,252
Net loss	—	—	—		—	(6,685)		(6,685)
Balances at December 31, 2023	33,437,296	$3		$437,132		$195			$(194,970)	$242,360

ContentsView on SEC.gov

The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.